Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of Moderate Buy from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month […]

Related Keywords

United States ,America ,American ,Jeffreyw Albers ,Piper Sandler ,Jared Gollob ,Raymond James Associates ,Kymera Therapeutics Inc ,Morgan Stanley ,American International Group Inc ,Mirae Asset Global Investments Co ,Group Plc ,Securities Exchange Commission ,Nasdaq ,Congress Asset Management Co ,Wells Fargo Company ,Kymera Therapeutics ,Get Free Report ,Wells Fargo ,Director Jeffrey ,Exchange Commission ,General Group Plc ,Asset Global Investments ,Asset Management ,American International Group ,International Group ,Get Free ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Ratings ,Consensus ,